Core Framework & Diagram The Future of Immunotherapy
7 月 24, 2026Core Framework & Diagram The Future of Immune Rejuvenation
7 月 24, 2026
The Future of Immune Rejuvenation
If the aged immune system could be 'reset' — what would change about human healthspan?
Articles 106–116 systematically covered how the immune system ages: thymus atrophy, declining T cell diversity, falling NK cell activity, continuously accumulating inflammaging.
This article is the 'other side' of that series — if aging is the problem, is 'reversing aging' the answer?
In traditional medicine frameworks, aging is an irreversible natural process, and medicine can only 'manage' it. But at the frontier of aging biology, this framework is being challenged: a growing body of research shows that certain dimensions of aging — especially immune system aging — under specific conditions, can be partially reversed or significantly slowed.
This isn't immortality science. It's the science of extending 'healthspan' (the years of maintaining high-quality health, not merely extending lifespan). The immune system is one of this science's most important target systems.
核心要点
01
Immune rejuvenation has three main routes: thymus regeneration (increasing T cell new supply), Senolytics (clearing senescent immune cells), and epigenetic reprogramming (rewriting the aging program) — the three complement each other, combined use maximizes effects.
02
TRIIM trial (2019) is the historic first step of thymus regeneration in humans: nine middle-aged men, after one year of intervention thymic volume increased, biological age averaged a reversal of two point five years. TRIIM-X (RCT) is underway, will provide more credible evidence.
03
Senolytics (D+Q, Fisetin) reduce SASP through intermittent clearance of senescent cells; multiple small-scale human trials showing IPF pulmonary function improvement and CKD kidney function indicator improvement, with Phase 2 randomized controlled trials underway.
04
Partial reprogramming (OSK factors, Sinclair et al. Nature 2020) reversed epigenetic aging of mouse retinal cells, restoring elderly mice's vision — immune rejuvenation's most radical future direction. Human trials expected to begin 2028–2032.
05
NK cell therapy has a unique position in the immune rejuvenation framework: currently the most direct, most actionable immune function restoration tool, not depending on thymus regeneration or epigenetic reprogramming, directly supplementing functional gaps through infusing vigorous NK cells.
06
The goal isn't immortality but 'healthspan' — maintaining high-quality immune health status for a longer time, delaying chronic disease onset, maintaining quality of life. This is an achievable, evidence-supported goal.
Art 147
The Future of Immune Aging Reversal
→
Art 148
Immunity and Longevity Science
→
